Roth Capital analyst Tony Butler initiates coverage on Fate Therapeutics (NASDAQ: FATE) with a Neutral rating and a price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE